When was Oncocross founded?

Oncocross was founded in 2015 and raised its 1st funding round 5 years after it was founded.

Where is Oncocross located?

Oncocross is headquartered in Seoul, South Korea.

Who is the current CEO of Oncocross?

Yi Rang Kim of Oncocross. They have also founded 1 company.

How many employees does Oncocross have?

As of Apr 30, 2026, the latest employee count at Oncocross is 16.

Is Oncocross a funded company?

Oncocross is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Sep 10, 2020.

When was the latest funding round of Oncocross?

Oncocross' latest funding was a $***** Series B round on Sep 10, 2020, with participation from 11 investors. Its primary sector is Oncology. In South Korea, the Oncology sector has seen $69.5M in funding in 2026 to date.

Where does Oncocross rank among its competitors?

Oncocross ranks 943rd amongst 3230 active competitors, of which 1115 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Oncocross?

Oncocross' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Oncocross - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Oncross is an AI-based drug discovery platform. The platform helps in matching and reporting of drugs, the user put data of the and then through AI the software gives matching and reporting of the drug interaction.

Website: www.oncocross.com/
Email ID: *****@oncocross.com
Phone Number: +82 **********

Key Metrics

Founded Year

2015

Location

Seoul, South Korea

Stage

Public

Total Funding

$13.9M in 1 round

Latest Funding Round

Series B, Sep 10, 2020, $*****

Investors

Cafe 24 & 12 more

Ranked

943^rd among 3230 active competitors

Employee Count

16 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 2972 more

Exit Details

Public

View Oncocross' full profile

Oncocross is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Oncocross Co., Ltd. CIN: 482-86-00109 , South Korea, Active	Jun 21, 2015	-	-	-

Oncocross got listed on Dec 18, 2024.

Click here to take a look at Oncocross's IPO in detail

Oncocross has raised a total funding of $13.9M over 1 round. Its latest funding round was a Series B round on Sep 10, 2020 for $*****. 11 investors participated in its latest round. Oncocross has 13 institutional investors.

Here is the list of recent funding rounds of Oncocross:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 10, 2020	7719216	Series B	3513808	3401360	9168615	9245097

Access funding benchmarks and valuations. Sign up today!

View details of Oncocross's funding rounds and investors

The founders of Oncocross are Yi Rang Kim and Jin Woo Choi. Yi Rang Kim is the CEO of Oncocross.

Here are the details of Oncocross' key team members:

Yi Rang Kim: Founder & CEO of Oncocross.
Jin Woo Choi: Co-Founder of Oncocross.

View details of Oncocross's Founder profiles and Board Members

Oncocross' employee count trend

Oncocross has 16 employees as of Apr 26. Here is Oncocross's employee count trend over the years:

Uncover Oncocross' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Oncocross include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Oncocross, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
943rd	Oncocross 2015, Seoul (South Korea), Public	Provider of AI-based drug discovery platform	$13.9M	GNTech Venture Capital, Magna & 11 others	42/100